Compare Stocks → Now Open: Crypto emergency update (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AADINASDAQ:GANXOTCMKTS:HBPCFNASDAQ:MBRXNASDAQ:OCUP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$1.80-1.1%$2.06$1.55▼$8.60$44.19M0.62376,019 shs150,086 shsGANXGain Therapeutics$3.15-0.9%$4.16$2.00▼$6.19$51.09M0.43157,918 shs78,261 shsHBPCFHelix BioPharma$0.14$0.14$0.14▼$0.15$31.59M-0.114 shsN/AMBRXMoleculin Biotech$4.54+6.1%$7.07$4.28▼$15.75$10.12M1.9530,838 shs49,637 shsOCUPOcuphire Pharma$1.67-4.0%$2.18$1.67▼$6.60$41.43M0.33219,676 shs239,603 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience-1.10%-9.55%-15.49%+10.43%-78.31%GANXGain Therapeutics-0.94%-6.25%-25.88%-5.41%-36.62%HBPCFHelix BioPharma0.00%0.00%-6.96%-5.03%-5.81%MBRXMoleculin Biotech+6.07%-5.02%-42.22%-44.66%-62.17%OCUPOcuphire Pharma-4.02%-6.70%-12.57%-38.83%-73.82%Now Open: Crypto emergency update (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAADIAadi Bioscience2.7338 of 5 stars3.34.00.00.01.93.30.6GANXGain Therapeutics3.2557 of 5 stars3.55.00.00.02.92.50.6HBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AMBRXMoleculin Biotech2.2342 of 5 stars3.53.00.00.02.80.01.3OCUPOcuphire Pharma1.662 of 5 stars3.52.00.00.00.61.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience2.50Moderate Buy$24.671,270.37% UpsideGANXGain Therapeutics3.00Buy$8.33164.55% UpsideHBPCFHelix BioPharmaN/AN/AN/AN/AMBRXMoleculin Biotech3.00Buy$35.00670.93% UpsideOCUPOcuphire Pharma3.00Buy$19.001,037.72% UpsideCurrent Analyst RatingsLatest MBRX, GANX, OCUP, HBPCF, and AADI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024MBRXMoleculin BiotechRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.004/1/2024GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/27/2024GANXGain TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/26/2024MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $20.003/20/2024OCUPOcuphire PharmaAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $20.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$24.35M1.81N/AN/A$4.29 per share0.42GANXGain Therapeutics$50K1,021.86N/AN/A$0.97 per share3.25HBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/AOCUPOcuphire Pharma$19.05M2.17N/AN/A$2.20 per share0.76Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.44N/AN/AN/A-270.04%-52.53%-44.29%5/8/2024 (Estimated)GANXGain Therapeutics-$22.27M-$1.71N/AN/AN/AN/A-193.03%-123.21%5/10/2024 (Estimated)HBPCFHelix BioPharma-$4.69M-$0.04N/A∞N/AN/A-817.64%-308.71%6/12/2024 (Estimated)MBRXMoleculin Biotech-$29.77M-$13.64N/AN/AN/AN/A-80.91%-67.69%5/9/2024 (Estimated)OCUPOcuphire Pharma-$9.99M-$0.48N/AN/AN/A-52.42%-22.30%-20.27%5/20/2024 (Estimated)Latest MBRX, GANX, OCUP, HBPCF, and AADI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023GANXGain Therapeutics-$0.32-$0.29+$0.03-$0.29N/AN/A3/13/2024Q4 2023AADIAadi Bioscience-$0.67-$0.60+$0.07-$0.60$6.46 million$6.33 million3/8/2024Q4 2023OCUPOcuphire Pharma-$0.07-$0.21-$0.14-$0.21$3.47 million$1.69 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/AOCUPOcuphire PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.724.48GANXGain Therapeutics0.043.593.59HBPCFHelix BioPharmaN/A1.461.46MBRXMoleculin BiotechN/A3.863.86OCUPOcuphire PharmaN/A13.3513.35OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%GANXGain Therapeutics11.97%HBPCFHelix BioPharmaN/AMBRXMoleculin Biotech15.52%OCUPOcuphire Pharma14.97%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience35.80%GANXGain Therapeutics11.00%HBPCFHelix BioPharma7.60%MBRXMoleculin Biotech6.70%OCUPOcuphire Pharma8.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience8924.55 million15.76 millionOptionableGANXGain Therapeutics2816.22 million14.44 millionOptionableHBPCFHelix BioPharma9229.44 million212.00 millionNot OptionableMBRXMoleculin Biotech152.23 million2.08 millionNot OptionableOCUPOcuphire Pharma1424.81 million22.65 millionOptionableMBRX, GANX, OCUP, HBPCF, and AADI HeadlinesSourceHeadlineOcuphire Pharma (NASDAQ:OCUP) Trading Down 4.3%americanbankingnews.com - April 16 at 1:52 AMFirst patient enrolled in LYNX-2 Phase 3 studyophthalmologytimes.com - April 12 at 4:15 PMFirst Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgeryglobenewswire.com - April 11 at 10:03 AMViatris launches Ryzumvi in USAthepharmaletter.com - April 1 at 11:54 AMOcuphire Announces Commercial Launch Of Ryzumvi In U.S. By Its Partner Viatrismarkets.businessinsider.com - April 1 at 11:54 AMOcuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatrisglobenewswire.com - April 1 at 7:14 AMOcuphire Pharma COO acquires $4.1k in company stockinvesting.com - March 27 at 4:21 PMOcuphire Pharma, Inc. (NASDAQ:OCUP) CFO Nirav S. Jhaveri Buys 10,000 Sharesinsidertrades.com - March 26 at 5:00 AMOcuphire Pharma, Inc. (NASDAQ:OCUP) CEO George Magrath Buys 25,000 Sharesinsidertrades.com - March 21 at 10:32 AMOCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 15 at 1:01 PMEarnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their Forecastsfinance.yahoo.com - March 13 at 8:02 AMBuy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy Treatmentmarkets.businessinsider.com - March 11 at 1:39 PMOcuphire Pharma Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - March 10 at 2:37 PMOcuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Updateglobenewswire.com - March 8 at 8:00 AMOcuphire (OCUP) to Report Q4 Earnings: What's in the Cards?msn.com - March 4 at 9:52 AM7 Under-the-Radar Biotech Stocks Gearing Up for Liftoffinvestorplace.com - February 26 at 3:20 PMOcuphire Pharma to Present in the BIO CEO & Investor Conferenceglobenewswire.com - February 23 at 8:00 AMOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - February 15 at 4:10 PMOcuphire Pharma Inc (OCUP)uk.investing.com - February 15 at 12:57 PMOcuphire Pharma Strengthens Leadership Team with Key Appointmentsfinance.yahoo.com - February 14 at 10:49 AMOcuphire Pharma Strengthens Leadership Team with Key Appointmentsglobenewswire.com - February 14 at 8:00 AMOcuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conferencefinance.yahoo.com - February 5 at 8:30 AMOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - January 24 at 5:10 PMOcuphire Pharma files for a $175M mixed securities shelfmsn.com - January 10 at 5:36 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAadi BioscienceNASDAQ:AADIAadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Gain TherapeuticsNASDAQ:GANXGain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies. The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds. It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Helix BioPharmaOTCMKTS:HBPCFHelix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.Moleculin BiotechNASDAQ:MBRXMoleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.Ocuphire PharmaNASDAQ:OCUPOcuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.